Surgify and the EIC Accelerator: A Safer Drill for Bone Surgery
Soft-tissue damage during head, neck and spine surgery costs about €4 billion a year in complications worldwide, according to ZEISS, Surgify's lead investor. Surgify Medical, an Aalto University spin-out founded in Espoo in 2017, makes the Surgify Halo, a burr with a built-in mechanism that it says cuts bone while protecting the soft tissue beneath.
The European Innovation Council granted €2,439,378 towards SSB2, a €3.48 million project that ran from September 2022 to August 2024. According to the CORDIS report, clinical trials at Kuopio and Helsinki university hospitals led to CE marking, the burr received FDA clearance, and production costs per piece fell by 40%. In May 2025 ZEISS Ventures led a €7 million Series A with the EIC Fund. Revenue reached €237,000 in 2025.
Company file
- Legal entity
- Surgify Medical Oy, business ID 2828662-9, Espoo
- Founded
- 2017, Aalto University spin-out
- CEO
- Visa Sippola
- Product
- Surgify Halo tissue-selective bone burrs, 3.0, 4.0 and 5.4 mm
- Investors
- ZEISS Ventures, Lednil, Cascara Ventures, EIC Fund
- EIC project
- SSB2, 1 Sep 2022 to 31 Aug 2024, closed
- EIC funding
- Blended finance; EIC Fund in the 2025 Series A
Where Surgify Stands Today
Surgify's news page tracks a company in its first sales years. It announced the Halo on sale in Germany and in two Scandinavian clinics in February 2025, distribution partners in Italy, the Netherlands and the United Kingdom later that year, and in March 2026 FDA clearance for a 3.0 mm burr. In September 2026 it hired an area director for the western United States and advertised for experienced US distributors.
The record
From clinical trial to sales in Europe and the US
Surgify won CE marking and FDA clearance during the EIC project and then raised a Series A with the EIC Fund.
- 2017Company foundedAalto University spin-out, Espoo
- Mar 2022EIC Accelerator cut-offSSB2: safety burrs for bone surgery
- Sep 2022EIC project startsTwo burr sizes, sensor research, production scale-up€2.44M grant
- Aug 2024EIC project endsCE mark and FDA clearance; unit cost down 40%
- Feb 2025Germany launchSurgify Halo on sale in Germany
- May 2025Series ALed by ZEISS Ventures with the EIC Fund€7M
- Mar 20263.0 mm burr clearedFurther FDA clearance
Surgify Medical news, ZEISS and CORDIS.
The Technology: A Burr That Spares Soft Tissue
The CORDIS report describes two burr sizes, 5.4 mm and 4 mm, for different operations, and research into "a sensor solution to predict and detect breakthrough moments during bone surgeries". It says the burrs now last 10 minutes of use instead of 5. The report states that "30% of bone drilling surgeries can lead to severe soft tissue injury", a figure it does not source.
"We are well positioned to bring our unique technology to more surgeons and patients internationally."
Visa Sippola, CEO, Surgify Medical, May 2025What the EIC Project Promised, and What CORDIS Shows
The EIC project
The EU paid 70% of a €3.48M project
SSB2 ran from September 2022 to August 2024. The award was blended finance.
CORDIS project 190102751. Values in € millions.
SSB2 promised "safety burrs for safer bone surgery" ready for market. The report lists clinical trials, CE marking and FDA clearance, supply agreements with Nouvag, GMI Corporation and Montemurro Utensili, doubled in-house assembly and the 40% cost cut. It gives no sales figures.
- European approvalDeliveredCE mark after clinical trials.
- US approvalDeliveredFDA clearance.
- Cheaper productionDeliveredCost per piece down 40%.
- Commercial scaleEarly€237K revenue in 2025.
What Has Happened Since the Award
The accounts
Sales are growing from a small base
Revenue in thousands of euros. The operating loss grew to €2.5 million in 2025 as the sales team expanded.
Finnish filed accounts via Asiakastieto.
The Money
ZEISS said the Series A brought Surgify's total funding to €14 million. The accounts summarised by Asiakastieto show revenue rising from €39,000 in 2023 to €95,000 in 2024 and €237,000 in 2025, while the operating loss grew from €0.8 million to €2.5 million; staff was 12 and the equity ratio 63% at the end of 2025.
The losses
Losses rose with the commercial push
Operating result in thousands of euros. Staff grew from 7 in 2022 to 12 in 2024 and 2025.
Finnish filed accounts via Asiakastieto.
What cannot be checked
How many burrs Surgify sells, how many hospitals use them, and how much the EIC Fund invested are not public.
Why Europe Should Care
The EIC paid most of the cost of taking a Finnish surgical tool through European and American approval, and a European optics group then led its first large round. The device is on the market in Europe and cleared in the US; the question now is whether surgeons buy it in volume.
What the project promised
Market-ready safety burrs for safer bone surgery.
What the record shows
CE and FDA approvals, distributors in several countries, a €7M Series A and revenue of €237,000.
The Verdict
Approved and selling, still small
SSB2 delivered what it promised: an approved product in Europe and the US at a lower cost. Surgify has since raised money and is building a sales network. Its revenue is growing fast but from a very low base.
Surgify Medical has not been asked for comment for this article. It is based entirely on company statements, Finnish company data and EU project data, linked throughout.
Industry
HealthMedical devices
- Focus
- Surgical devices
- Technologies
- Precision mechanics
- Keywords
- Bone burrs
- Spine surgery
- Neurosurgery
- Soft tissue protection